32 p.ill.,LIST OF FIGURES 2 -- LIST OF TABLES 2 -- LIST OF ABBREVIATIONS 3 --  SCIENTIFIC REPORT 4 -- 1 INTRODUCTION 4 -- 2 METHODS 5 -- 2.1 THE USE OF SCENARIOS IN THE DRUG PRICING PROJECT 5 -- 2.2 RECRUITMENT OF PARTICIPANTS 6 -- 2.3 INTERVIEWS 6 -- 2.4 ANALYSIS OF THE INTERVIEWS 7 -- 2.4.1 Approach 7 -- 2.4.2 General framing of the drug pricing problematique 7 -- 2.4.3 Building blocks for alternative drug development and pricing mechanisms 10 -- 2.5 THE SCENARIO DEVELOPMENT PROCESS 14 -- 3 RESULTS 15 -- 3.1 RESULTS FROM THE FIRST SCENARIO BUILDING WORKSHOP 15 -- 3.1.1 Refinement of the purpose served by the projected drug development and pricing system 15 -- 3.1.2 Refinement of the collection of functional building blocks 15 -- 3...
Building futures literacy in the drug policy domain contributes to enhanced preparedness and will su...
The first paper, Pharmaceutical R&D: a real option approach, considers the process of pharmaceutical...
This report is an individual extension of the group report done by our team for Parexel, covering a ...
32 p.ill.,LIST OF FIGURES 2 -- LIST OF TABLES 2 -- LIST OF ABBREVIATIONS 3 --  SCIENTIFIC RE...
Planning future policy for medicines poses difficult problems. The main players in the drug business...
Pharmaceutical companies are facing several major interrelated challenges, the most strategic being ...
This paper uses scenario-planning methodology to consider the long-term future of the global pharmac...
The future of medicines is likely determined by an array of scientific, socioeconomic, policy, medic...
BACKGROUND AND AIMS. Drug development has been classically associated with large pharmaceutical comp...
The role of clinical pharmacy in the health care system is changing rapidly. This change is almost u...
INTRODUCTION: R&D costs as an element of medicines' pricing play a prominent role in the discussions...
This study evaluates whether an adaptive development and licensing approach to drug development, com...
Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstra...
For decades, patients, doctors, ethicists, and other interested parties have debated the economics o...
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Building futures literacy in the drug policy domain contributes to enhanced preparedness and will su...
The first paper, Pharmaceutical R&D: a real option approach, considers the process of pharmaceutical...
This report is an individual extension of the group report done by our team for Parexel, covering a ...
32 p.ill.,LIST OF FIGURES 2 -- LIST OF TABLES 2 -- LIST OF ABBREVIATIONS 3 --  SCIENTIFIC RE...
Planning future policy for medicines poses difficult problems. The main players in the drug business...
Pharmaceutical companies are facing several major interrelated challenges, the most strategic being ...
This paper uses scenario-planning methodology to consider the long-term future of the global pharmac...
The future of medicines is likely determined by an array of scientific, socioeconomic, policy, medic...
BACKGROUND AND AIMS. Drug development has been classically associated with large pharmaceutical comp...
The role of clinical pharmacy in the health care system is changing rapidly. This change is almost u...
INTRODUCTION: R&D costs as an element of medicines' pricing play a prominent role in the discussions...
This study evaluates whether an adaptive development and licensing approach to drug development, com...
Market access and pricing of pharmaceuticals are increasingly contingent on the ability to demonstra...
For decades, patients, doctors, ethicists, and other interested parties have debated the economics o...
Healthcare remains a national crisis. Among the associated issues are the high cost of medications a...
Building futures literacy in the drug policy domain contributes to enhanced preparedness and will su...
The first paper, Pharmaceutical R&D: a real option approach, considers the process of pharmaceutical...
This report is an individual extension of the group report done by our team for Parexel, covering a ...